NPC is inherited in an autosomal recessive manner, as established in the GeneReviews certified data for this condition. This packet does not contain a certified causative-gene claim; accordingly, no specific genes are named here. The disorder results in a failure of proper cholesterol trafficking, leading to the characteristic accumulation of unesterified cholesterol in the late endosomal and lysosomal compartment. Certain variant types and locations within associated genes have been observed in correlation with specific age-of-onset subtypes, including early-infantile and late-infantile forms, based on published genotype-phenotype correlation data, though the specific gene identities fall outside the certified scope of this packet.

Diagnosis of NPC is guided by consensus clinical management guidelines developed under the auspices of the International Niemann-Pick Disease Alliance. Clinicians may suspect NPC based on age-stratified clinical presentations. In the early infantile period, fetal ascites, neonatal liver disease, prolonged cholestatic jaundice, and pulmonary infiltrates are suggestive. One study found that 27% of infants initially diagnosed with idiopathic neonatal cholestasis and 8% of all infants with cholestasis had NPC. The differential diagnosis of neonatal and infantile presentations includes acquired conditions such as biliary atresia, congenital infections, malignancies, and other genetic disorders. Late infantile and older presentations require differentiation from other neurologic and metabolic conditions. Clinical management guidelines include recommendations for both clinical and laboratory approaches to diagnosis.

No curative therapy for NPC currently exists. Clinical management guidelines for NPC have been published, and revised guidelines are noted to be in development to incorporate recently approved targeted therapies. Miglustat is described as approved for management of neurologic manifestations of NPC in several countries, though it is noted as not currently FDA approved as a standalone treatment for NPC in the United States. Arimoclomol and levacetylleucine are referenced in the context of recently approved targeted therapies being incorporated into revised guidelines, though specific approval details and eligibility criteria are not fully detailed in this packet. Agents to avoid in NPC management include drugs that cause excessive salivation, drugs that may exacerbate seizures or interact with anti-seizure medications, alcohol, and drugs that exacerbate ataxia.

NPC is described as a slowly progressive lysosomal disorder. Its principal manifestations are age dependent, with visceral features predominating early in life and neurologic features becoming increasingly prominent from late infancy onward. Progressive dementia is noted as an eventual manifestation in affected individuals. The GeneReviews clinical description characterizes the neurologic course as including progressive cognitive impairment alongside motor and other neurologic features, though it may initially be subtle. Specific data on life expectancy, mortality, or long-term survival are not certified within this packet. Prognosis may vary by subtype and age of neurologic onset, including late infantile and adult neurologic onset forms, but quantitative outcome data are not provided in the available certified sources.

The research landscape for NPC includes 144 classified publications, with basic science and preclinical research identified as the dominant category. Published literature includes work related to gene therapy, biomarker investigation, and recent clinical trial activity, as well as 23 review articles and 14 case reports. One active clinical trial is currently listed in this packet: NCT06985212, a national multicentre study of the natural history of acid sphingomyelinase deficiency in adults and children, sponsored by Dr. Wladimir Mauhin, with a status of not yet recruiting as of the packet date, a planned start date of May 2025, and an anticipated completion date of April 2035. Intrathecal 2-hydroxypropyl-beta-cyclodextrin has been investigated as a therapy under study, though a controlled clinical trial did not demonstrate a statistically significant difference between the treated and control groups. Patient support organizations include the Ara Parseghian Medical Research Foundation (parseghian.org) and the Hide & Seek Foundation for Lysosomal Disease Research (hideandseek.org).